Vmbook Online ordering

Prima Biomed Ltd

Prima Biomed Ltd is an Australian-headquartered biotechnology company that focuses on the research, development, and commercialization of immunotherapies for cancer treatment. The company's lead product is known as CAN008, an autologous dendritic cell therapy that targets the cancer-associated antigen, mucin 1 (MUC1). This immunotherapy is designed to stimulate the patient's immune system to recognize and attack cancer cells expressing MUC1.

Prima Biomed was founded in 1988 and has listed its shares on the Australian Securities Exchange (ASX) under the ticker symbol "PBZ." Additionally, the company's American Depository Shares (ADS) were listed on the NASDAQ stock exchange until December 2021, under the ticker symbol "PBMD." However, the company has delisted its ADS from NASDAQ, as of December 20, 2021, following its acquisition by Imugene Limited, another Australian biotechnology company.

The acquisition of Prima Biomed by Imugene aims to create a leading immuno-oncology company, combining Imugene's extensive portfolio of cancer vaccine candidates with Prima Bimed's immunotherapy expertise and CAN008 program. The combined entity will operate under the Imugene name and continue to develop and advance its oncology pipeline through preclinical and clinical stage studies.

It's essential to stay updated on the latest company information and developments, as the merger may impact the company's activities, financials, and stock price. You can find the latest news, investor presentations, and financial reports on both Imugene and Prima Biomed's websites or through their investor relations channels. Additionally, you can monitor the combined company's progress and updates through stock market news and financial news platforms.